➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Express Scripts
McKesson
Merck

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

IOVERSOL - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for ioversol and what is the scope of patent protection?

Ioversol is the generic ingredient in five branded drugs marketed by Liebel-flarsheim and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for ioversol. One supplier is listed for this compound.

Recent Clinical Trials for IOVERSOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 0
Instituto Mexicano del Seguro SocialPhase 3
MallinckrodtPhase 4

See all IOVERSOL clinical trials

Pharmacology for IOVERSOL

US Patents and Regulatory Information for IOVERSOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 019710-002 Dec 30, 1988 RX Yes Yes   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988 RX Yes Yes   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 020923-004 May 13, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IOVERSOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
Johnson and Johnson
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.